Article Details

Quentis Therapeutics Debuts with $48 Million Series A Financing to Advance First-in-Class ...

Retrieved on: 2018-02-26 20:22:30

Tags for this article:

Click the tags to see associated articles and topics

Quentis Therapeutics Debuts with $48 Million Series A Financing to Advance First-in-Class .... View article details on hiswai:

Excerpt

<div>Quentis is pioneering first-in-class cancer immunotherapies that modulate endoplasmic reticulum (ER) stress response pathways in the tumor microenvironment. The Series A proceeds will support the advancement of Quentis' lead program, a small molecule IRE1α inhibitor, into the clinic in 2019 and ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo